Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies.In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers.Recently, BsAbs 142 have represented a significant advancement in improving clinical outcomes.BsAbs are designed to target two different anti